Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc.RLMD · filed Jul 5, 2022
- Accession no.
- 0001213900-22-037231
- Filed
- Jul 5, 2022
- Trade date
- Jun 30-Jul 1, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $559.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2022 | Common Stock | MOption exerciseAcquired | +16,012 | $16.00 | +$256,192 | 104,786 | Direct | |
| Jun 30, 2022 | Common Stock | SSaleDisposed | −5,314 | $19.37F3 | −$102,932.18 | 99,472 | Direct | |
| Jun 30, 2022 | Common Stock | SSaleDisposed | −10,698 | $19.01F4 | −$203,368.98 | 88,774 | Direct | |
| Jul 1, 2022 | Common Stock | MOption exerciseAcquired | +13,755 | $16.00 | +$220,080 | 102,529 | Direct | |
| Jul 1, 2022 | Common Stock | SSaleDisposed | −839 | $18.48F5 | −$15,504.72 | 101,690 | Direct | |
| Jul 1, 2022 | Common Stock | SSaleDisposed | −8,848 | $18.45F6 | −$163,245.6 | 92,842 | Direct | |
| Jul 1, 2022 | Common Stock | SSaleDisposed | −4,068 | $18.32F7 | −$74,525.76 | 88,774 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2022 | Common Stock | MOption exerciseDisposed | −16,012 | $0.00 | $0 | 13,755 | Direct | |
| Jul 1, 2022 | Common Stock | MOption exerciseDisposed | −13,755 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Sales prices range from $19.20 to $19.51 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
Sales prices range from $19.00 to $19.15 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
Sales prices range from $18.47 to $18.53 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
Sales prices range from $18.45 to $18.47 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
Sales prices range from $18.26 to $18.44 per share, inclusive.
Referenced by the price of 1 transaction in Table I.